Recruiting Clinical Trials

Displaying 31 - 40 of 227 result(s)
Study Title Condition Phase Location
Randomized, Single-dose, Open-label, Two-part, Two-period, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric With an Adult Formulation of Branaplam and to Investigate the Adult Formulation in Fed and Fasted St ... Healthy Volunteers Phase 1
  • Country: 
    United Kingdom
Phase I, Open-label, Multicenter Study to Evaluate the Imaging Performance, Safety, Biodistribution and Dosimetry of [68Ga]-FF58 in Adult Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma Phase 1
  • Country: 
    United States
  • Country: 
    France
Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)] Prostatic Neoplasms, Prostate Cancer, Recurrence Phase 3
  • Country: 
    France
  • Country: 
    Spain
  • Country: 
    Switzerland
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study Breast Cancer Not Given
  • Country: 
    France
A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) Primary Immune Thrombocytopenia Phase 3
  • Country: 
    Singapore
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome Myelodysplastic Syndromes Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    China
  • Country: 
A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan Prostate Cancer Phase 2
  • Country: 
    Japan
A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Br ... Asthma Phase 2
  • Country: 
    Bulgaria
  • Country: 
    Hungary
  • Country: 
    Poland
  • Country: 
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments Advanced Solid Tumors Phase 1
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Canada
  • Country: 
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Prostatic Neoplasms Phase 3
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Belgium
  • Country: